I am incredibly grateful to be able to collaborate with so many brilliant and devoted colleagues to work to obtain high-quality, evidence-based data to guide the treatment and care of patients with NMDAR Autoimmune #Encephalitis. Let’s do this, #Neurology! 🤝🧠.

📣 Saturday August 16 is for PATIENTS, designed by PATIENTS, for free, on what is most helpful in autoimmune neurologic conditions:. -Navigating insurance + finances.-Partnering with primary care .-Symptom management.-Getting outside to play, adaptively.-Updates/Tips from experts.

RT @GreenJournal: In this episode of the Neurology Podcast: The July 2025 recall features four episodes on systems and innovation in delive….

RT @StavrosKara: 🧠I love this new #Neurology Minute series sharing highlights from the @AANmember Capitol Hill Report - it’s another good w….

RT @UofUNeurology: We’re excited to welcome our new PGY-1s! 🧠 This talented group is kicking off their journey, and we’re thrilled to have….

RT @neurology_live: Now enrolling patients across the US and Europe, the phase 2b ExTINGUISH trial is a multicenter study evaluating 300-mg….

RT @aszelikovich: -Graduate Fellowship: ✅.-Record a podcast: ✅. Excited to share my 1st podcast episode with the Neurology Minute Podcast T….

ATTN: Neurologists (esp. new trainees!):. Get up to date on everything you need to know about stroke in one single Delayed Recall Episode of the @GreenJournal Podcast 👇. #TimeWellSpent. @AANmember @Neurohosp @neurocritical @NMatch2026.

🧠🎙️:Thanks to the Resident & Fellow Section Team for walking us all thru this case - from acute diagnosis and management thru a thoughtful etiologic investigation 👇.

🧠🎙️: A simple plan provided to caregivers of what to do if the patient has a seizure makes all the difference - . Lesson: Take 5 minutes and type out the plan for your patients with seizures 👇.

Never underestimate the importance of arranging a timely outpatient followup visit - with Neurology and/or Primary Care 🤝🫶.

@extinguishtrial @wearesrna @TheSumairaFDN @TheMOGProject @Philly_Chapman @OAERG1 @EdenDoraTrust @RareDiseases @ncats_nih_gov @NINDStrials @nih_strokenet Open access article:.

RT @UofUNeurology: In 1959, Leonard Jarcho, MD, was named to the neurology division at @UofUHealth. By 1965, he led the creation of the De….

✋ 🛑 We must do better. If available clinical trials are not discussed and offered to patient/loved ones BEFORE immunotherapy is given, then it is NOT informed care. KNOWLEDGE = POWER . @extinguishtrial

👉Early use of first- and second-line immunotherapy has increased since 2019 but functional outcomes have only improved modestly since 2019. And yet, patients are often subjected to the full “kitchen sink”of immunotherapies, often without any time given to assess effect 🤔.4/.

We evaluated changes in treatment strategies and outcomes in NMDAR Encephalitis since the previous comprehensive review in 2019. 👉No significant change was noted in mortality or relapse rates!. 3/

In NMDAR Encephalitis, equipoise may be obscured by undue weight assigned to treatment recommendations based on expert opinion. 🧐. Although helpful in framing an approach, “consensus guidelines” may unintentionally obfuscate the need for high quality studies. 2/

Just published 👉. A NEWLY updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote 🧠🔥 . Why is this paper so important ? . 1/

This is great work!! . If we only had a high quality, ongoing, prospective randomized clinical trial of a B-cell targeting monoclonal to definitively test this in NMDAR encephalitis… 😉 . 👉Currently enrolling: @extinguishtrial for NMDAR Encephalitis 🧠 🔥.

Ever had that experience where someone said “it can’t be CNS vasculitis because the angiography is normal”?. Welllll… take a listen to this👇. 🎙️🧠 @AANmember.

RT @AANmember: In this episode, hear from new AAN President @NataliaRostMD as she outlines her vision and key priorities for her two-year t….